American Society of Hematology 2019 guidelines for sickle cell disease: cardiopulmonary and kidney disease
Top Cited Papers
Open Access
- 3 December 2019
- journal article
- research article
- Published by American Society of Hematology in Blood Advances
- Vol. 3 (23), 3867-3897
- https://doi.org/10.1182/bloodadvances.2019000916
Abstract
Prevention and management of end-organ disease represent major challenges facing providers of children and adults with sickle cell disease (SCD). Uncertainty and variability in the screening, diagnosis, and management of cardiopulmonary and renal complications in SCD lead to varying outcomes for affected individuals. These evidence-based guidelines of the American Society of Hematology (ASH) are intended to support patients, clinicians, and other health care professionals in their decisions about screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. ASH formed a multidisciplinary guideline panel that included 2 patient representatives and was balanced to minimize potential bias from conflicts of interest. The Mayo Evidence-Based Practice Research Program supported the guideline development process, including performing systematic evidence reviews up to September 2017. The panel prioritized clinical questions and outcomes according to their importance for clinicians and patients. The panel used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, including GRADE evidence-to-decision frameworks, to assess evidence and make recommendations, which were subject to public comment. The panel agreed on 10 recommendations for screening, diagnosis, and management of cardiopulmonary and renal complications of SCD. Recommendations related to anticoagulation duration for adults with SCD and venous thromboembolism were also developed. Most recommendations were conditional due to a paucity of direct, high-quality evidence for outcomes of interest. Future research was identified, including the need for prospective studies to better understand the natural history of cardiopulmonary and renal disease, their relationship to patient-important outcomes, and optimal management.Keywords
This publication has 121 references indexed in Scilit:
- The prevalence of hypertension and abnormal kidney function in children with sickle cell disease –a cross sectional reviewBMC Nephrology, 2013
- Associated risk factors for silent cerebral infarcts in sickle cell anemia: low baseline hemoglobin, sex, and relative high systolic blood pressureBlood, 2012
- Chronic Kidney Disease and Albuminuria in Children with Sickle Cell DiseaseClinical Journal of the American Society of Nephrology, 2011
- Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacityBlood, 2011
- Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studiesBritish Journal of Haematology, 2010
- Response of patients with sickle cell anaemia and end-stage renal disease to erythropoietin treatmentClinical Kidney Journal, 2010
- Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell diseaseBritish Journal of Haematology, 2009
- Hematologic, biochemical, and cardiopulmonary effects of l‐arginine supplementation or phosphodiesterase 5 inhibition in patients with sickle cell disease who are on hydroxyurea therapyEuropean Journal of Haematology, 2009
- GRADE: an emerging consensus on rating quality of evidence and strength of recommendationsBMJ, 2008
- Relative systemic hypertension in patients with sickle cell disease is associated with risk of pulmonary hypertension and renal insufficiencyAmerican Journal of Hematology, 2007